Loading
A phase 3 trial of DFP-10917 run by Delta-Fly Pharma, Inc., terminated.
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage is a phase 3 interventional study registered as NCT03926624 by Delta-Fly Pharma, Inc., with 167 participants enrolled, started 2019-11-22. Conditions recorded: Leukemia, Myeloid, Acute. Interventions recorded: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax and Cladribine.
Shares DFP-10917, Delta-Fly Pharma, Acute myeloid leukaemia and the tag pipeline.
Shares DFP-10917, Delta-Fly Pharma, Acute myeloid leukaemia and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/